Repository logo
 

Epithelial IL-23R Signaling Licenses Protective IL-22 Responses in Intestinal Inflammation.

Published version
Peer-reviewed

Change log

Authors

Aden, Konrad 
Rehman, Ateequr 
Falk-Paulsen, Maren 
Secher, Thomas 
Kuiper, Jan 

Abstract

A plethora of functional and genetic studies have suggested a key role for the IL-23 pathway in chronic intestinal inflammation. Currently, pathogenic actions of IL-23 have been ascribed to specific effects on immune cells. Herein, we unveil a protective role of IL-23R signaling. Mice deficient in IL-23R expression in intestinal epithelial cells (Il23R(ΔIEC)) have reduced Reg3b expression, show a disturbed colonic microflora with an expansion of flagellated bacteria, and succumb to DSS colitis. Surprisingly, Il23R(ΔIEC) mice show impaired mucosal IL-22 induction in response to IL-23. αThy-1 treatment significantly deteriorates colitis in Il23R(ΔIEC) animals, which can be rescued by IL-22 application. Importantly, exogenous Reg3b administration rescues DSS-treated Il23R(ΔIEC) mice by recruiting neutrophils as IL-22-producing cells, thereby restoring mucosal IL-22 levels. The study identifies a critical barrier-protective immune pathway that originates from, and is orchestrated by, IL-23R signaling in intestinal epithelial cells.

Description

Keywords

Animals, Colitis, Dextran Sulfate, Dysbiosis, Epithelial Cells, Gene Expression Regulation, Granulocytes, Interleukin-23, Interleukins, Intestinal Mucosa, Isoantibodies, Male, Mice, Mice, Knockout, Neutrophils, Pancreatitis-Associated Proteins, Receptors, Interleukin, Signal Transduction, Stem Cells, Interleukin-22

Journal Title

Cell Rep

Conference Name

Journal ISSN

2211-1247
2211-1247

Volume Title

16

Publisher

Elsevier BV
Sponsorship
European Research Council (648889)
European Research Council (260961)
Wellcome Trust (106260/Z/14/Z)
This work was supported by DFG Excellence Cluster Inflammation at Interfaces; the SFB877 B9, the SFB 1182 C2 project, and the BMBF IHEC DEEP project TP2.3 and 5.2 (to P.R.); the European Research Council under the European Community’s Seventh Framework Programme (FP7/2007- 2013)/ERC grant agreement 260961 (to A.K.); the National Institute for Health Research Cambridge Biomedical Research Centre, ERC CoG GA 648889, and WTIA 106260-Z-14-Z (to A.K.); NIH DK53056, DK44319, and DK088199 (to R.S.B.); and the Fondation pour la Recherche Medicale (to M.C.).